These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 24429006)

  • 1. 'Dear Healthcare Professional' letters may not be effective REMS communication tool.
    Thompson CA
    Am J Health Syst Pharm; 2014 Feb; 71(3):177-8. PubMed ID: 24429006
    [No Abstract]   [Full Text] [Related]  

  • 2. With REMS, what goes up can come down.
    Thompson CA
    Am J Health Syst Pharm; 2011 May; 68(9):783-4. PubMed ID: 21515857
    [No Abstract]   [Full Text] [Related]  

  • 3. Shared REMS programs expanded in 2012.
    Traynor K
    Am J Health Syst Pharm; 2013 Feb; 70(4):298, 303. PubMed ID: 23370134
    [No Abstract]   [Full Text] [Related]  

  • 4. Where are risk evaluation and mitigation strategies headed?
    Johnson PE
    Am J Health Syst Pharm; 2010 Sep; 67(18):1511. PubMed ID: 20811027
    [No Abstract]   [Full Text] [Related]  

  • 5. Risk evaluation and mitigation strategies: challenges and opportunities for health-system pharmacists.
    Stubbings J; Joshi RA; Hoffman JM
    Am J Health Syst Pharm; 2010 Sep; 67(18):1547-54. PubMed ID: 20811034
    [No Abstract]   [Full Text] [Related]  

  • 6. Implications of Risk Evaluation and Mitigation Strategy (REMS) programs for managed care pharmacy.
    ; Gandhi G; Chon A; Johnson N; Kidder PA; Lee P; Leung K; Ma I; Ness S; Sampsel E; Schlaifer M; Seifert R; Sternaman DB
    J Manag Care Pharm; 2012 Apr; 18(3):268-75. PubMed ID: 22468736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NCCN Oncology Risk Evaluation and Mitigation Strategies White Paper: Recommendations for Stakeholders.
    Johnson PE; Dahlman G; Eng K; Garg R; Gottlieb S; Hoffman JM; Howell P; Jahanzeb M; Johnson S; Mackler E; Rubino M; Sarokhan B; Marc Stewart F; Tyler T; Vose JM; Weinstein S; Li EC; Demartino J;
    J Natl Compr Canc Netw; 2010 Sep; 8 Suppl 7():S7-S27. PubMed ID: 20947724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The US Food and Drug Administration's Risk Evaluation and Mitigation Strategy (REMS) Program - Current Status and Future Direction.
    Wu J; Juhaeri J
    Clin Ther; 2016 Dec; 38(12):2526-2532. PubMed ID: 27914632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDA urged to reduce REMS program burdens.
    Traynor K
    Am J Health Syst Pharm; 2015 Nov; 72(22):1916-21. PubMed ID: 26541942
    [No Abstract]   [Full Text] [Related]  

  • 10. How the FDA handles GI drug safety.
    Lewis JH
    Am J Gastroenterol; 2012 Aug; 107(8):1264; author reply 1264-5. PubMed ID: 22859005
    [No Abstract]   [Full Text] [Related]  

  • 11. Medication guides leave their REMS programs behind.
    Traynor K
    Am J Health Syst Pharm; 2012 Feb; 69(4):272-3. PubMed ID: 22302249
    [No Abstract]   [Full Text] [Related]  

  • 12. APhA 2011 REMS white paper: Summary of the REMS stakeholder meeting on improving program design and implementation.
    American Pharmacists Association ; Bough M
    J Am Pharm Assoc (2003); 2011; 51(3):340-58. PubMed ID: 21555285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Communication of medical product risk: how effective is effective enough?
    Goldman SA
    Drug Saf; 2004; 27(8):519-34. PubMed ID: 15154825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Food and Drug Administration Amendments Act of 2007: drug safety and health-system pharmacy implications.
    Meyer BM
    Am J Health Syst Pharm; 2009 Dec; 66(24 Suppl 7):S3-5. PubMed ID: 19966078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparisons of Food and Drug Administration and European Medicines Agency risk management implementation for recent pharmaceutical approvals: report of the International Society for Pharmacoeconomics and outcomes research risk benefit management working group.
    Lis Y; Roberts MH; Kamble S; J Guo J; Raisch DW
    Value Health; 2012 Dec; 15(8):1108-18. PubMed ID: 23244814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk evaluation and mitigation strategies: impact on patients, health care providers, and health systems.
    Shane R
    Am J Health Syst Pharm; 2009 Dec; 66(24 Suppl 7):S6-S12. PubMed ID: 19966079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New botulinum toxin approved with REMS.
    Thompson CA
    Am J Health Syst Pharm; 2010 Sep; 67(18):1486. PubMed ID: 20811019
    [No Abstract]   [Full Text] [Related]  

  • 18. Examination of risk evaluation and mitigation strategies and drug safety in the US.
    Rodriguez-Monguio R; Spielberger K; Seoane-Vazquez E
    Res Social Adm Pharm; 2014; 10(1):232-8. PubMed ID: 23611865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Class-wide REMS for extended-release and long-acting opioids: potential impact on pharmacies.
    Matthews ML
    J Am Pharm Assoc (2003); 2013; 53(1):e1-7. PubMed ID: 23636166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Documenting an adverse drug reaction.
    Smith LS
    Nursing; 2005 Oct; 35(10):22. PubMed ID: 16205246
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.